healthNewsغير مصنف

U.S. agency told Mylan that EpiPen was misclassified

WASHINGTON (Reuters) – A U.S. federal health agency said on Wednesday it had “expressly advised” Mylan NV that the drugmaker had improperly classified its EpiPen emergency allergy treatment in a way that allowed it to pay lower rebates to state health programs.

اظهر المزيد

مقالات ذات صلة

زر الذهاب إلى الأعلى